• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:AU2004216298A1
    申请号:U2004216298
    申请日:2004-02-27
    公开日:2004-09-10
    发明作者:Eiichi Miyauchi；Akihiko Saito
    申请人:Chugai Pharmaceutical Co Ltd；
    IPC主号:A61K9-00
    专利说明:
    VERIFICATION OF TRANSLATION I, (name & address of translator) Takako KOISO, Patent Attorney, of YUASA AND HARA, (Section 206, New Ohtemachi Bldg. , 2nd Floor) 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo, JAPAN state the following: I am fluent in both the English and Japanese languages and capable of translating documents from one into the other of these languages. The attached document is a true and accurate English translation to the best of my knowledge and belief of: [lease tick appropriate box (es) that apply to this application] W the description and claims of PCT Application No. PM'/JP90041009499 D- including amendments made during Chapter I of PCT proceedings including amendments made during Chapter II of PCT proceedings I state that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true. Signature. Takako KOISO Date: June 20, 2005 SPECIFICATION STABILIZED PROTEIN-CONTAINING FORMULATIONS TECHNICAL FIELD 5 The present invention relates to stable protein containing formulations. More specifically, the present invention relates to stable protein-containing formulations containing a poloxamer as a surfactant. 10. BACKGROUND ART With the development of genetic engineering technology, it has become possible to use physiologically active proteins such as antibodies, enzymes, hormones and cytokines as pharmaceutical products. To supply them in 15 stable amounts with high quality, it is necessary to establish preparation conditions and storage conditions under which the structure and activity can be maintained. Generally, a problem encountered during storage of proteins is a deterioration phenomenon such as the 20 formation of insoluble aggregates and must be prevented. For example, antibodies such as immunoglobulins, monoclonal antibodies and humanized antibodies are unstable proteins liable to physical or chemical changes such as association or aggregation under stresses of 25 filtration, concentration and heat during purification and formulation processes as well as stresses of heat, light and transportation during storage of stock solutions or formulations. - 1- When antibodies are to be obtained by genetic engineering techniques, antibody-producing cells are cultured in bulk and purified to give an antibody containing solution, which is then stored frozen and 5 thawed before formulation. However, the antibody content remaining in such a solution decreased as antibody dimers or insoluble particles or foreign insoluble matters were formed during repeated freeze/thaw cycles or antibodies were degraded to form degradation products during long 10 term storage. In order to inhibit the formation of such foreign insoluble matters and to obtain stable protein-containing formulations, the use of surfactants is indispensable, and especially, such surfactants as polysorbates 20 and 80 15 have been widely used. In the case of readily oxidizable protein formulations, however, antioxidants such as L methionine had to be included in addition to polysorbate 80 (JPA No. 2000-247903, J. Pharm. Sci. 90:3 (2001)) because polysorbate 80 tends to oxidize proteins (PDA J. 20 Pharm. Sci. Technol. 50:3(1996); Formulation, Characterization, and Stability of Protein Drugs. Plenum Press, New Yolk, (1996)), thereby lowering the biological activity of antibody formulations.. The addition of antioxidants required complex operations such as strict 25 determination of the specifications and amounts of the antioxidants. Thus, it would be desirable to provide a surfactant capable of inhibiting the oxidation of proteins without -2adding antioxidants and capable of inhibiting the formation of foreign insoluble matters in protein formulations. Lyophilized formulations can inhibit the oxidation of proteins (for example, JPA No. 2000-247903), 5 but there are great demands for convenient solution formulations eliminating the reconstitution step and it would also be desirable to provide protein-containing formulations that are stable even as solution formulations. An object of the present invention is to find a 10 surfactant capable of inhibiting the oxidation of proteins without adding antioxidants to maintain the biological activity of the proteins and also capable of inhibiting the formation of foreign insoluble matters in protein formulations and to provide a stabilized protein 15 containing formulation containing said surfactant. DISCLOSURE OF THE INVENTION As a result of careful studies to achieve the above object, we accomplished the present invention on the basis 20 of the finding that the biological activity of proteins can be maintained without causing oxidation of the proteins in the absence of antioxidants and the formation of foreign insoluble matters can be inhibited in protein containing formulations by adding a poloxamer as a 25 surfactant. Accordingly, the present invention provides: (1) a protein formulation containing a poloxamer as a surfactant; -3- (2) the protein formulation as defined in (1) above wherein the poloxamer is poloxamer 188; (3) the protein formulation as defined in (1) or (2) above, which is a solution formulation; 5 (4) the protein formulation as defined in any one of (1) to (3) above wherein the protein is an immunoglobulin; (5) the protein formulation as defined in (4) above wherein the immunoglobulin is a humanized antibody; (6) the protein formulation as defined in (4) above 10 wherein the immunoglobulin is an anti-tissue factor antibody; (7) the protein formulation as defined in (6) above wherein the anti-tissue factor antibody is a humanized anti-tissue factor antibody; 15 (8) the protein formulation as defined in any one of (1) to (9) above, which is free from antioxidant as an additive; (9) a method for maintaining the biological activity in a protein formulation without adding an antioxidant and 20 for inhibiting the formation of foreign insoluble matters by adding a poloxamer as a surfactant; (10) the protein formulation as defined in any one of (1) to (3) above wherein the protein is granulocyte colony-stimulating factor; and 25 (11) the protein formulation as defined in any one of (1) to (3) above wherein the protein is parathyroid hormone. -4- BRIEF EXPLANATION OF THE DRAWINGS Figure 1 shows changes in biological activity over time in anti-human tissue factor antibody solution formulations containing various surfactants. 5 Figure 2 represents anion-exchange chromatograms of anti-human tissue factor antibody solution formulations containing poloxamer 188 or polysorbate 80. Figure 3 shows the effect of adding L-methionine on the activity loss induced by polysorbate 80 in an anti 10 human tissue factor antibody as compared with the effect of adding a poloxamer. Figure 4 represents chromatograms showing the influence of polysorbate 80, polysorbate 20 or poloxamer 188 on the oxidation of granulocyte colony-stimulating 15 factor. Figure 5 represents chromatograms showing the influence of polysorbate 80, polysorbate 20 or poloxamer 188 on the oxidation of parathyroid hormone. 20 THE MOST PREFERRED EMBODIMENTS OF THE INVENTION As used herein, "protein-containing formulation" means a formulation containing a protein, preferably a physiologically active protein as an active ingredient and prepared for administration to animals such as humans, 25 including both lyophilized formulations and solution formulations. Proteins used in formulations of the present invention include, but not limited to, antibodies, enzymes, -5cytokines and hormones. Specifically, they include, but not limited to, hematopoietic factors such as granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO) 5 and thrombopoietin; cytokines such as interferons, IL-1 and IL-6; immunoglobulins; monoclonal antibodies; humanized antibodies; tissue plasminogen activator (TPA); urokinase; serum albumin; blood coagulation factor VIII; leptin; insulin; and stem cell growth factor (SCF). Among 10 those proteins, hematopoietic factors such as G-CSF and EPO, parathyroid hormone (PTH) and immunoglobulins are preferred, especially antibodies. Among antibodies, anti-tissue factor antibodies are especially preferred. Proteins used in formulations of the present 15 invention have substantially the same biological activities as those of physiologically active proteins of mammals, especially humans, and include those derived from natural sources and preferably those genetically engineered. Genetically engineered proteins may have the 20 same amino acid sequences as those of natural proteins or may contain deletion, substitution or addition of one or more amino acids in said amino acid sequences while maintaining said biological activities. Physiologically active proteins also include those chemically modified 25 with PEG or the like. Proteins having a sugar chain are especially preferred. The sugar chain may be derived from any source, but preferably those added to mammalian cells. Mammalian - 6 cells include, for example, Chinese hamster ovary (CHO) cells, BHK cells, COS cells, human-derived cells, etc., among which CHO cells are most preferred. When the protein is EPO, EPO may be prepared by any 5 process, e.g. it may be extracted from human urine and isolated and purified by various techniques or may be produced by genetic engineering techniques (for example, JPA No. SHO 61-12288) in Chinese hamster ovary (CHO) cells, BHK cells, COS cells, human-derived cells or the like and 10 then extracted and isolated and purified by various techniques. EPO chemically modified with PEG or the like is also included (see International Patent Application Publication No. W090/12874). EPO having no sugar chain and chemically modified with PEG or the like is also 15 included. EPO analogs are also included, in which EPO has been modified to increase the number of one or more glycosylation sites at the N-linked carbohydrate chain binding site or O-linked.carbohydrate binding site in the amino acid sequence of EPO (for example, see JPA No. HEI 20 8-151398 and JPA No. HEI 8-506023). Moreover, the amount of sugar chains may be increased by increasing the content of sialic acid or the like without changing the number of sugar chain-binding sites. When the protein is G-CSF, any high-purity human 25 G-CSF can be used. G-CSF in the present invention may be prepared by any process, e.g., they may be extracted from cultures of a human tumor cell line and isolated and purified by various techniques or may be produced by -7genetic engineering techniques in bacterial cells such as E. coli; yeast cells; animal culture cells such as Chinese hamster ovary (CHO), C127 or COS cells and then extracted and isolated and purified by various techniques. G-CSF is 5 preferably produced by genetic recombination in E. coli, yeast or CHO cells, most preferably by genetic recombination in CHO cells. G-CSF chemically modified with PEG or the like is also included (see International Patent Application Publication No. W090/12874). 10 When the protein is an antibody, the antibody is not specifically limited so far as it binds to a desired antigen, and mouse antibodies, rat antibodies, rabbit antibodies, sheep antibodies, chimeric antibodies, humanized antibodies, human antibodies and the like can be 15 used as appropriate. The antibodies may be polyclonal or monoclonal, but preferably monoclonal because homogeneous antibodies can be stably produced. Polyclonal and monoclonal antibodies can be prepared by processes well known to those skilled in the art. 20 Hybridomas producing monoclonal antibodies can be basically constructed by known techniques as follows. A desired antigen or a cell expressing a desired antigen is used as an immunizing antigen to immunize host cells according to a standard immunization technique, and the 25 resulting immunized cells are fused to known parent cells by a standard cell fusion technique, and then the fused cells are screened for monoclonal antibody-producing cells (hybridomas) by a standard screening method. Construction -8of hybridomas can be performed according to the method of e.g. Milstein et al. (Kohler. G. and Milstein, C., Methods Enzymol. (1981) 73: 3-46). If the antigen has low immunogenicity, it can be bound to an immunogenic 5 macromolecule such as albumin and used for immunization. Recombinant antibodies can be used, which are produced by transforming a host with a suitable vector containing an antibody gene cloned from a hybridoma using genetic engineering techniques (see e.g. Carl, A. K. 10 Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Specifically, the cDNA sequences for the variable regions (V regions) of an antibody are synthesized from mRNA of a hybridoma using a reverse 15 transcriptase. Once DNA sequences encoding the V regions of the antibody of interest have been obtained, they may be linked to the DNA sequences encoding the constant regions (C regions) of the antibody of interest and integrated into an expression vector. Alternatively, the 20 DNA sequences encoding the V regions of the antibody may be integrated into an expression vector containing the DNA sequences for the C regions of the antibody. They are integrated into the expression vector in such a manner that they can be expressed under the control of regulatory 25 regions such as enhancers and promoters. Then, a host cell can be transformed with this expression vector to express the antibody. In the present invention, recombinant antibodies, -9i.e. antibodies artificially modified to reduce antigenicity in humans or to attain other purposes, such as chimeric antibodies and humanized antibodies can be used. These modified antibodies can be prepared by known 5 processes. Chimeric antibodies consist of the heavy and light chain variable regions of an antibody from a non human mammal such as a mouse and the heavy and light chain constant regions of a human antibody and can be obtained by linking the DNA sequences encoding the variable regions 10 of the mouse antibody to the DNA sequences for the constant regions of the human antibody and transforming a host with an expression vector containing the linked sequences to allow it to produce a chimeric antibody. Humanized antibodies are also called reshaped human 15 antibodies and obtained by grafting the complementarity determining regions (CDRs) of an antibody from a non-human mammal such as a mouse into the complementarity determining regions of a human antibody and typical gene recombination techniques for preparing them are also known. 20 Specifically, DNA sequences designed to link the CDRs of a mouse antibody to the framework regions (FRs) of a human antibody are synthesized by PCR from several oligonucleotides prepared to have terminal overlapping regions. The resulting DNA sequences are linked to the 25 DNA sequences encoding the constant regions of the human antibody and then integrated into an expression vector, which is transformed into a host to allow it to produce a reshaped antibody (see European Patent Application - 10 - Publication No. EP 239400, International Patent Application Publication No. WO 96/02576). The FRs of the human antibody linked by the CDRs are selected in such a manner that the complementarity-determining regions form 5 an appropriate antigen-binding site. If necessary, reshaped humanized antibodies may have some amino acid changes in the framework regions of the variable regions so that the complementarity-determining regions form an appropriate antigen-binding site (Sato, K. et al., Cancer 10 Res. (1993) 53, 851-856). Methods for obtaining human antibodies are also known. For example, a desired human antibody having a binding activity for a desired antigen can be obtained by in vitro immunizing human lymphocytes with the desired 15 antigen or a cell expressing the desired antigen and fusing the immunized lymphocytes to human myeloma cells such as U266 (see JPB No. HEI 1-59878). A desired human antibody can also be obtained by immunizing a transgenic animal having all human antibody gene repertoires with an 20 antigen (see International Patent Application Publications Nos. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, WO 96/33735). Methods for obtaining a human antibody by panning using a human antibody library are also known. For example, phages binding to an antigen can 25 be selected by expressing the variable regions of a human antibody as single chain antibody fragments (scFv) on phage surfaces by a phage display method. The DNA sequences encoding the variable regions of the human - 11 antibody binding to the antigen can be determined by analyzing the genes of the selected phages. A whole human antibody can be obtained by preparing a suitable expression vector on the basis of the determined DNA 5 sequences of the scFv fragments binding to the antigen. These methods have already been well known from WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388. When an antibody is to be prepared by transforming a 10 preliminarily isolated antibody gene into a suitable host, the suitable host can be used in combination with an expression vector. Suitable eukaryotic cells used as hosts include animal cells, plant cells and fungal cells. Known animal cells include (1) mammalian cells such as CHO, 15 COS, myeloma, BHK (baby hamster kidney), HeLa and Vero cells; (2) amphibian cells such as Xenopus oocytes; or (3) insect sells such as sf9, sf21 and Tn5. Known plant cells include cells of Nicotiana such as Nicotiana tabacum, which can be used as callus cultures. Known fungal cells 20 include yeasts such as Saccharomyces spp., e.g. Saccharomyces serevisiae and filamentous fungi such as Aspergillus spp., e.g. Aspergillus niger. Prokaryotic cells can be used as producing systems using bacterial cells. Known bacterial cells include E. coli and Bacillus 25 subtilis. Antibodies can be obtained by transforming these cells with an antibody gene of interest and culturing the transformed cells in vitro. Antibodies contained in stabilized formulations of - 12 the present invention include, but not limited to, anti IL-6 receptor antibodies, anti-HM1.24 antigen monoclonal antibodies, anti-parathyroid hormone related peptide antibodies (anti-PTHrP antibodies), anti-tissue factor 5 antibodies, etc. Preferred reshaped humanized antibodies for use in the present invention include humanized anti-IL-6 receptor antibodies (hPM-1) (see International Patent Application Publication No. W092-19759), humanized anti-HM1.24 antigen 10 monoclonal antibodies (see International Patent Application Publication No. W098-14580) and humanized anti-parathyroid hormone related peptide antibodies (anti PTHrP antibodies) (see International Patent Application Publication No. W098-13388). 15 We prepared human/mouse chimeric antibodies consisting of the variable regions (V regions) of a mouse monoclonal antibody against human tissue factor and the constant regions (C regions) of a human antibody as well as humanized antibodies consisting of the complementarity 20 determining regions in the light chain (L chain) variable region and the heavy chain (H chain) variable region of a mouse monoclonal antibody against human tissue factor transferred into a human antibody, and reported that these could be expected as excellent therapeutic agents for DIC, 25 arterial thrombosis and venous thrombosis (W099/51743, WO01/24626). Especially preferred are humanized anti human tissue factor antibodies comprising a combination of humanized H chain version i and humanized L chain version - 13 b2 described in W099/51743, which are recombinant antibodies produced by CHO cells. Many anti-human tissue factor antibodies have already been reported (W099/51743, W088/07543, W096/40921, W098/40408, WO01/70984). They can 5 be prepared by methods known to those skilled in the art because their antigen tissue factor has already been known (Ito T et al., J. Biochem. 114, 691-696, (1993)). These anti-human tissue factor antibodies are also preferred antibodies for use in the present invention. 10 Antibodies contained in formulations of the present invention may belong to any immunoglobulin class, preferably IgG such as IgG1, IgG2, IgG3 and IgG4. As used herein, "antibody-containing solution" may be a solution containing any antibody, whether 15 biologically derived or recombinant, preferably a culture medium in which mammalian cells such as CHO cells containing an antibody have been cultured, or a solution obtained by subjecting such a medium to a given treatment such as partial purification (bulk solution), or the 20 solution formulation prepared for administration to animals such as humans as defined above. As used herein, "foreign insoluble matters" mean the readily detectable foreign insoluble matters from which solution formulations must be free and clear when observed 25 in containers with unaided eyes at a position of light intensity of approximately 1000 luxes under an incandescent lamp as defined in the section of Foreign Insoluble Matter Test for Injections in the part of - 14 - General Tests, Processes and Apparatus in the Japanese Pharmacopoeia. As used herein, "the biological activity of the antibody" means the antibody's ability to bind to its 5 antigen, and can be determined by antigen-neutralizing activity assays. Formulations retaining the biological activity of the antibody mean that they retain 60% or more, preferably 70% or more, still more preferably 80% or more, most preferably 90% or more of the biological activity of 10 the antibody stock after accelerated testing at 25 0 C for 6 months when the antibody is a humanized anti-human tissue factor antibody. In the present invention, purity tests of antibody formulations can be performed by gel filtration 15 chromatography and anion-exchange chromatography described below. In protein-containing formulations of the present invention, a high biological activity can be maintained without causing oxidation of the proteins in the absence 20 of antioxidants and the formation of foreign insoluble matters can be inhibited in the protein-containing formulations by adding a poloxamer as a surfactant. Poloxamers are nonionic surfactants consisting of a series of block copolymers of ethylene oxides and 25 propylene oxides of the general formula below:
    HO(C
    2
    H
    4 0)a(C 3
    H
    6 0)b(C 2
    H
    4 0)aH Poloxamers include poloxamers 124, 188, 237, 338 and 407 described in USP (US Pharmacopoeia), among which - 15 poloxamer 188 is especially preferred in the present invention. Poloxamer 188 described in USP is a compound of the formula above wherein a is 80, b is 27, with an average molecular weight of 7680-9510, and poloxamer 188 5 described in BP (British Pharmacopoeia) is a compound of the formula above wherein a is about 75, b is about 30, with an average molecular weight of 8350. In addition, EP (European Pharmacopoeia) describes poloxamers 182, 184 and 331. Pluronics (trademark for poloxamers available from 10 BASF) such as Pluronics L35, L43, L44, L61, L62, L64, F68, L81, P84, P85, F87, F88, L92, F98, L101, P103, P104, P105, F108, L121, P123 and F127 are also included in poloxamers in the present invention. Poloxamers have previously been used as emulsifiers 15 for fat emulsion preparations for intravenous injection or solubilizers for keeping the clarity of elixirs or syrups in pharmaceutical formulations, but have not been used as stabilizers for protein-containing formulations. The amount of poloxamers to be added depends on the 20 types of the poloxamers used and the concentration and type of the protein, but the amount of poloxamer 188 is typically 0.001-100 mg/mL, preferably 0.005-50 mg/mL, more preferably 0.01-10 mg/mL. In protein-containing formulations of the present 25 invention, the use of a poloxamer as a surfactant eliminates the need for adding antioxidants such as L-methionine as required when polysorbates were used. Protein-containing formulations of the present - 16 invention may contain amino acids as stabilizers. The amino acids include, but not limited to, leucine, tryptophan, serine, glutamic acid, arginine, histidine and lysine and salts thereof. 5 In order to inhibit the formation of dimers during freeze/thaw cycles, formulations of the present invention may further contain sugar alcohols such as mannitol and sorbitol; and nonreducing oligosaccharides, e.g. nonreducing disaccharides such as sucrose and trehalose or 10 nonreducing trisaccharides such as raffinose. Especially, nonreducing oligosaccharides are preferred. Preferred nonreducing oligosaccharides are nonreducing disaccharides, more preferably sucrose and trehalose. Preferably, antibody-containing solution 15 formulations of the present invention are substantially free from proteins such as human serum albumin or purified gelatin as stabilizers. Antibody formulations of the present invention preferably have a pH of 4-8, more preferably 5-7.5. 20 However, the pH depends on the antibody contained and is not limited to these values. Formulations of the present invention may further contain isotonizing agents, e.g., polyethylene glycol; and sugars such as dextran, mannitol, sorbitol, inositol, 25 glucose, fructose, lactose, xylose, mannose, maltose, sucrose, trehalose and raffinose. Antibody-containing solution formulations of the present invention may further contain diluents, - 17 solubilizing agents, excipients, pH-modifiers, soothing agents, buffers, sulfur-containing reducing agents, antioxidants or the like, if desired. For example, sulfur-containing reducing agents include N-acetylcysteine, 5 N-acetylhomocysteine, thioctic acid, thiodiglycol, thioethanolamine, thioglycerol, thiosorbitol, thioglycolic acid and salts thereof, sodium thiosulfate, glutathione, and sulfhydryl-containing compounds such as thioalkanoic acid having 1 to 7 carbon atoms. Antioxidants include 10 erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, a-tocopherol, tocopherol acetate, L-ascorbic acid and salts thereof, L-ascorbyl palmitate, L-ascorbyl stearate, sodium bisulfite, sodium sulfite, triamyl gallate, propyl gallate or chelating agents such 15 as disodium ethylenediamine tetraacetate (EDTA), sodium pyrophosphate and sodium metaphosphate. Other common additives may also be contained, e.g., inorganic salts such as sodium chloride, potassium chloride, calcium chloride, sodium phosphate, potassium phosphate and sodium 20 bicarbonate; and organic salts such as sodium citrate, potassium citrate and sodium acetate. Formulations of the present invention can be prepared by dissolving these components in an aqueous buffer known in the field of solution formulations such as 25 a phosphate buffer (preferably sodium monohydrogen phosphate - sodium dihydrogen phosphate system) and/or a citrate buffer (preferably sodium citrate buffer) to prepare a solution formulation. The concentration of the - 18 buffer is typically 1-500 mM, preferably 5-100 mM, more preferably 10-50 mM. Antibody-containing solution formulations of the present invention are normally administered via parenteral 5 routes such as injection (e.g. subcutaneous, intravenous, intramuscular or intraperitoneal injection) or percutaneous, mucosal, nasal or pulmonary administration, but may also be orally administered. Protein-containing formulations of the present 10 invention may be either lyophilized formulations or solution formulations, preferably solution formulations. Solution formulations can be normally supplied in sealed and sterilized plastic or glass containers having a defined volume such as vials, ampules or syringes or a 15 large volume such as bottles. In terms of convenience, prefilled syringes are preferred. The amount of antibodies contained in formulations of the present invention is typically 0.1-200 mg/ml, preferably 1-120 mg/ml, depending on the type of the 20 disease to be treated, the severity of the disease, the age of the patient and other factors. As shown in the examples below, solution formulations of the present invention can retain the biological activity of the antibody formulations at a high 25 level without adding antioxidants and inhibit the formation of foreign insoluble matters by adding a poloxamer as a surfactant. The following examples further illustrate the - 19 present invention without, however, limiting the scope of the invention thereto. Various changes and modifications can be made by those skilled in the art. in the light of the description herein, and such changes and modifications 5 are also included in the present invention. EXAMPLES Samples 1. Antibody sample 10 A humanized anti-human tissue factor antibody comprising a combination of humanized H chain version i and humanized L chain version b2 described in W099/51743 was used as an anti-human tissue factor antibody. The anti-human tissue factor antibody used in the examples 15 below is a recombinant antibody produced by CHO cells and belonging to the IgG4 class. 2. Granulocyte colony-stimulating factor (G-CSF) The granulocyte colony-stimulating factor used was 20 produced by a genetic engineering technique in Chinese Hamster Ovary (CHO) cells using a gene recombination method and extracted and isolated/purified. 3. Parathyroid hormone (PTH) 25 Parathyroid hormone having 1-84 residues was prepared by the method described in W09014415. Test Methods - 20 - (1) TF-neutralizing activity assay Tissue factor (TF) is a blood coagulation factor VII receptor expressed on cell surfaces and has been positioned as a substantial trigger of the blood 5 coagulation reaction. Tissue factor activates blood coagulation factors IX and X via formation of a complex with blood coagulation factor VII. Thus, the biological activity of humanized anti-human tissue factor antibodies can be assayed by the method described below using a blood 10 coagulation factor VIIa solution and a blood coagulation factor X solution. 1. The following solutions were prepared. 1) A.B.(Assay Buffer): TBS (pH 7.6) containing 5 mmol/L 15 CaCl 2 , 0.1% BSA. 2) Mixed solution of Factor VIIa & Thromborel S: Factor VIIa and Thromborel S were diluted with A.B. to 0.1 PEU/mL and 0.42 mg/mL, respectively. 3) Factor X solution: Factor X was diluted with A.B. to 20 0.25 PEU/mL. 4) Mixed Testzyme chromogenic substrate S-2222 solution:.A 1.5 mg/mL chromogenic substrate S-2222 solution was mixed with water and an aqueous polybrene solution in a ratio of 1:1:2. 25 2. The mixed solution of factor VIIa & Thromborel S was dispensed into a plate at 60 pL/well and allowed to stand at room temperature for 60 minutes. 3. The anti-human tissue factor antibody stock solution - 21 - (standard solution) and sample solutions diluted with Factor X solution were dispensed into the plate at 40 pL /well and allowed to stand at room temperature for 30 minutes. 5 4. The reaction was stopped by adding 10 pL/well of a 0.5 mol/L EDTA solution, and then the mixed Testzyme chromogenic substrate S-2222 solution was dispensed into the plate at 50 pL/well and allowed to stand at room temperature for 30 minutes. 10 5. The absorbance at 405 nm - 655 nm was measured. 6. The biological activity of each test sample was calculated as a percentage of the value of the standard solution based on calibration curve analysis. 15 Abbreviations TBS: Tris Buffered Saline BSA: Bovine Serum Albumin EDTA: Ethylenediamine Tetraacetic Acid 20 (2) Ion-exchange chromatography (IEC) Assay conditions were as follows. Column: DEAE-NPR (4.6 mm I.D.x 3.5 cm) Mobile phase: A: 50 mmol/L Tris buffer, pH 8.0 25 B: 50 mmol/L Tris buffer + 500 mmol/L NaCl, pH 8.0 Gradient: 0-5 min Solution B 0% 5-40 min Solution B 0 -- 50% - 22 - Flow rate: 1.0 mL/min Detection: UV absorption at 280 nm Sample load: equivalent to 100 pg 5 (3) Analysis of foreign insoluble matters Solution formulations in containers were observed with unaided eyes at a position of light intensity of approximately 1000 luxes under an incandescent lamp as defined in the section of Foreign Insoluble Matter Test 10 for Injections in the part of General Tests, Processes and Apparatus in the Japanese Pharmacopoeia. Example 1: Effects of adding surfactants on biological activity 15 Changes over time in the biological activity of anti-human tissue factor antibody solution formulations containing various surfactants were tested. Samples (pH 6.0) containing 2.3 mg/mL of the anti-human tissue factor antibody in an acetate buffer and 0.5 mg/mL of polysorbate 20 20 or 80 (both manufactured by company A) or poloxamer 188 (manufactured by company B) as a surfactant were tested for biological activity (TF-neutralizing activity) after storage at 5 0 C for 14 days and at 40 0 C for 14 days. A group containing no surfactant was also tested in the same 25 manner for comparison. The results are shown in Figure 1. In contrast to the formulation containing polysorbate 80, which showed a marked loss in the biological activity of the anti-human tissue factor antibody, the formulation - 23 containing poloxamer 188 retained a comparable activity to that of the formulation containing no surfactant. An activity loss was also observed in the formulation containing polysorbate 20 known as an injectable 5 surfactant in the field. Example 2: Effects of surfactants on biological activity and purity The effects of adding surfactants on the biological 10 activity and purity of anti-human tissue factor antibody solution formulations were tested. Samples (pH 5.5) containing 10 mg/mL of the anti-human tissue factor antibody in an acetate buffer and 0.5 mg/mL of polysorbate 80 (manufactured by company C) or poloxamer 188 15 (manufactured by company D) as a surfactant were tested for biological activity by the TF-neutralizing activity assay and for purity by ion-exchange chromatography (IEC) after accelerated testing at 25 0 C for 6 months. The anti human tissue factor antibody stock solution (bulk) without 20 accelerated testing was also tested in the same manner for comparison. The results are shown in Figure 2. The biological activity of the formulation containing poloxamer 188 was 92% of the biological activity of the anti-human tissue factor antibody stock 25 solution, while the biological activity of the formulation containing polysorbate 80 was 52%. In ion-exchange chromatography, the main peak dropped and a new peak (indicated by an arrow in Figure 2) - 24 appeared immediately before the main peak in the anti-human tissue factor antibody solution formulation containing polysorbate 80. The peak fraction appearing immediately before the main peak was attributed to a 5 derivative containing some oxidized amino acid residues. However, the formulation containing poloxamer 188 retained a chromatogram similar to that of the anti-human tissue factor antibody stock solution. These results showed that poloxamer 188 is superior 10 to polysorbate 80 in both biological activity and purity. Example 3: Effect of adding L-methionine on the activity loss induced by polysorbate 80 in the anti-human tissue factor antibody as compared with the effect of adding a 15 poloxamer The effect of adding L-methionine on the activity loss induced by polysorbate 80 in the anti-human tissue factor antibody solution formulation was tested and compared with the formulation containing poloxamer 188. 20 Samples (pH 5.5) containing 10 mg/mL of the anti-human tissue factor antibody in an acetate buffer and 1) 0.5 mg/mL of polysorbate 80, 2) 0.5 mg/mL of polysorbate 80 plus 5 mg/mL of L-methionine, or 25 3) 0.5 mg/mL of poloxamer 188 were prepared. Each sample was tested for biological activity by the TF-neutralizing activity assay after accelerated - 25 testing at 25 0 C for 6 months, and compared with the biological activity of the anti-human tissue factor antibody stock solution (bulk). The results are shown in Figure 3. The activity 5 loss induced by polysorbate 80 was inhibited by adding L-methionine. The sample containing poloxamer 188 showed a biological activity comparable to or higher than that of the sample containing polysorbate 80 and L-methionine. 10 Example 4: Effects of surfactants on foreign insoluble matters The effects of adding surfactants on the formation of foreign insoluble matters in anti-human tissue factor antibody solution formulations were tested. Samples 15 (pH 6.0) containing 10 mg/mL of the anti-human tissue factor antibody in an acetate buffer and 0.5 mg/mL of polysorbate 80 (manufactured by company C) or poloxamer 188 (manufactured by company D) as a surfactant were tested for foreign insoluble matters immediately after 20 preparation and after storage at 5 0 C for 24 months. A group containing no surfactant was also tested in the same manner for comparison. The results are shown in Table 1. The number of vials in which foreign insoluble matters were observed among 5 sample vials was shown. Insoluble 25 matters were visually observed immediately after preparation in the sample containing no surfactant. However, no formation of foreign insoluble matters was observed in the samples containing poloxamer 188 and - 26 polysorbate 80. Table 1 Surfactant None Poloxamer 188 polysorbate 80 Initial 5/5 0/5 0/5 5 0 C-24M 5/5 0/5 0/5 5 (4) Experiment on the stabilization of the protein by a poloxamer Various surfactants were added to the granulocyte colony-stimulating factor solution formulation and parathyroid hormone solution formulation described above 10 to evaluate their effects on the oxidation of granulocyte colony-stimulating factor and parathyroid hormone. Example 5: Influences of surfactants on the oxidation of granulocyte colony-stimulating factor 15 The influences of surfactants on granulocyte colony-stimulating factor solution formulations were tested. Samples (pH 6.5) containing 0.25 mg/mL of colony-stimulating factor in a phosphate buffer and 0.05% of polysorbate 80 (manufactured by company A), polysorbate 20 20 (manufactured by company A), or poloxamer 188 (manufactured by company B) as a surfactant were tested for the content of oxidized derivatives of granulocyte colony-stimulating factor by reverse-phase chromatography (RPC) after accelerated testing at 25 0 C for 5 weeks. - 27 - Assay conditions were as follows. Column: DAISOPAK SP-300-5-C4-P (4.6 mm I.D. x 25 cm) Mobile phase: A acetonitrile:water:trifluoroacetic acid = 400:600:1 5 B acetonitrile:water:trifluoroacetic acid = 800:200:1 Gradient: 0-25 min Solution B 20 - 90% 25-40 min Solution B 90 - 90% 40-41 min Solution B 90 - 20% 10 41-60.min Solution B 20% Flow rate: 0.3 mL/min Load: 10 pL Column temperature: 35 0 C Detection wavelength: UV absorption at 215 nm 15 The results are shown in Figure 4. Reverse-phase chromatography showed that oxidized derivatives (indicated by an arrow in Figure 4) appeared immediately before the main peaks of the granulocyte 20 colony-stimulating factor solution formulations containing various surfactants. These peak fractions were attributed to derivatives of granulocyte colony-stimulating factor containing some oxidized amino acid residues. The content of oxidized derivatives was the highest 25 in the sample containing polysorbate 20, followed by polysorbate 80 and then poloxamer 188. Example 6: Influences of surfactants on the oxidation of - 28 parathyroid hormone The influences of surfactants on parathyroid hormone solution formulations were tested. Samples (pH 5.0) containing 0.25 mg/mL of parathyroid hormone in a citrate 5 buffer and 0.05% of polysorbate 80 (manufactured by company A), polysorbate 20(manufactured by company A), or poloxamer 188 (manufactured by company B) as a surfactant were tested for the content of oxidized derivatives of parathyroid hormone by reverse-phase chromatography (RPC) 10 after accelerated testing at 40 0 C for 2 weeks. Assay conditions were as follows. Column: YMC-Pack ODS A-312 (4.6 mm I.D. x 15 cm) Mobile phase: A acetonitrile:water:trifluoroacetic acid = 0:1000:1 15 B acetonitrile:water:trifluoroacetic acid = 600:400:1 Gradient: 0-40 min Solution B 40 - 60% 40-42 min Solution B 60 - 60% 42-42.5 min Solution B 60 - 40% 20 42.5-60 min Solution B 40% Flow rate: 1.0 mL/min Load: 10 pL Column temperature: 25 0 C Detection wavelength: UV absorption at 215 nm 25 The results are shown in Figure 5. Reverse-phase chromatography showed that oxidized derivatives (indicated by arrows in Figure 5) appeared - 29 immediately before the main peaks of the parathyroid hormone solution formulations containing various surfactants. These peak -fractions were attributed to derivatives of parathyroid hormone containing some 5 oxidized amino acid residues. The content of oxidized derivatives was the highest in the sample containing polysorbate 20, followed by polysorbate 80 and then poloxamer 188. These results showed that poloxamer 188 is superior 10 to polysorbates in the antioxidant effect on protein solution formulations. INDUSTRIAL APPLICABILITY Stabilized protein-containing formulations of the 15 present invention show neither biological activity loss nor formation of foreign insoluble matters even after long-term storage. They are stable formulations in which the generation of oxidized derivatives of proteins is effectively inhibited. 20 - 30 -
    权利要求:
    Claims (11)
    [1] 1. A protein formulation containing a poloxamer as a surfactant. 5
    [2] 2. The protein formulation of claim 1 wherein the poloxamer is poloxamer 188.
    [3] 3. The protein formulation of claim 1 or 2, which is a solution formulation.
    [4] 4. The protein formulation of any one of claims 1 to 3. 10 wherein the protein is an immunoglobulin.
    [5] 5. The protein formulation of claim 4 wherein the immunoglobulin is a humanized antibody.
    [6] 6. The protein formulation of claim 4 wherein the immunoglobulin is an anti-tissue factor antibody. 15
    [7] 7. The protein formulation of claim 6 wherein the anti-tissue factor antibody is a humanized anti-tissue factor antibody.
    [8] 8. The protein formulation of any one of claims 1 to 9, which is free from antioxidant as an additive. 20
    [9] 9. A method for maintaining the biological activity in a protein formulation without adding an antioxidant and for inhibiting the formation of foreign insoluble matters by adding a poloxamer as a surfactant.
    [10] 10. The protein formulation of any one of claims 1 to 3 25 wherein the protein is granulocyte colony-stimulating factor.
    [11] 11. The protein formulation of any one of claims 1 to 3 wherein the protein is parathyroid hormone. - 31 -
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2004216298B2|2009-04-23|Stabilized protein-containing formulations
    US8840884B2|2014-09-23|Antibody-containing solution pharmaceuticals
    US10316096B2|2019-06-11|Stabilized antibody-containing formulations
    EP2311492B1|2017-10-04|Antibody-containing stabilized preparations
    US7682608B2|2010-03-23|Stabilized preparations containing antibody
    同族专利:
    公开号 | 公开日
    CA2517310A1|2004-09-10|
    US20060159653A1|2006-07-20|
    JPWO2004075913A1|2006-06-01|
    CA2517310C|2015-11-24|
    JP2010215664A|2010-09-30|
    CN100353997C|2007-12-12|
    EP1598074A4|2011-10-26|
    JP4607010B2|2011-01-05|
    KR20050113199A|2005-12-01|
    US8765124B2|2014-07-01|
    WO2004075913A1|2004-09-10|
    EP1598074A1|2005-11-23|
    EP1598074B1|2019-01-02|
    US20090264629A1|2009-10-22|
    CN1744912A|2006-03-08|
    JP5377431B2|2013-12-25|
    HK1084340A1|2006-07-28|
    US9968677B2|2018-05-15|
    KR101235507B1|2013-02-20|
    AU2004216298B2|2009-04-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4839341A|1984-05-29|1989-06-13|Eli Lilly And Company|Stabilized insulin formulations|
    JP2577742B2|1986-07-18|1997-02-05|中外製薬株式会社|Stable granulocyte colony-stimulating factor containing preparation|
    GR871067B|1986-07-18|1987-11-19|Chugai Pharmaceutical Co Ltd|Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor|
    JPS63146828A|1986-07-18|1988-06-18|Chugai Pharmaceut Co Ltd|Stable granulocyte colony stimulating factor-containing preparation|
    NO176799C|1986-12-23|1995-05-31|Kyowa Hakko Kogyo Kk|DNA encoding a polypeptide, recombinant plasmid that encodes and can express a polypeptide and method for producing this polypeptide|
    DE3863908D1|1987-11-27|1991-08-29|Akzo Nv|STABILIZATION OF ANTIBODY.|
    WO1995003783A1|1990-03-06|1995-02-09|Houston Biotechnology Incorporated|Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract|
    IT1255460B|1992-07-28|1995-11-02|Poli Ind Chimica Spa|PHARMACEUTICAL COMPOSITIONS IN THE FORM OF MICROEMULSIONS OR BIOADHESIVE LIPOSOMIAL DISPERSIONS FOR THE TRANSMUCOSAL ADMINISTRATION OF PEPTIDAL SUBSTANCES AND PHARMACOLOGICALLY ACTIVE PROTEINS|
    JP3047948B2|1992-12-07|2000-06-05|株式会社ツムラ|Composition for nasal administration of peptides|
    US5358708A|1993-01-29|1994-10-25|Schering Corporation|Stabilization of protein formulations|
    CA2155005C|1993-02-02|1999-04-06|Weldon Courtney Mcgregor|Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant|
    JP3862295B2|1993-09-30|2006-12-27|独立行政法人理化学研究所|Anti-obesity agent|
    FR2710841B1|1993-10-05|1995-11-17|Oreal|Cosmetic or pharmaceutical composition for the skin, anhydrous and stable, based on retinol and its use for the treatment of skin diseases.|
    FR2733914B1|1995-05-11|1997-08-01|Sanofi Sa|STABLE LIQUID COMPOSITION CONTAINING URATE OXYDASE AND LYOPHILIZED COMPOSITION FOR ITS PREPARATION|
    US6267958B1|1995-07-27|2001-07-31|Genentech, Inc.|Protein formulation|
    DE19538687A1|1995-10-17|1997-04-24|Boehringer Mannheim Gmbh|Stable pharmaceutical dosage forms containing parathyroid hormone|
    JPH09174348A|1995-12-22|1997-07-08|Nitto Seiko Co Ltd|Screw fastening unit|
    KR100210509B1|1996-01-10|1999-07-15|성재갑|Composition for sustained release of animal growth hormone and method for preparation thereof|
    AU1558197A|1996-02-01|1997-08-22|Chugai Seiyaku Kabushiki Kaisha|Preventives and remedies for thrombocytopenia|
    JP4053107B2|1996-02-01|2008-02-27|中外製薬株式会社|Preventive and therapeutic agents for thrombocytopenia|
    EP0852951A1|1996-11-19|1998-07-15|Roche Diagnostics GmbH|Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals|
    TW536403B|1997-03-24|2003-06-11|Glaxo Group Ltd|An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy|
    US6171586B1|1997-06-13|2001-01-09|Genentech, Inc.|Antibody formulation|
    JPH1168624A|1997-08-08|1999-03-09|Sony Corp|Equalizing circuit|
    WO1999016421A1|1997-09-29|1999-04-08|Inhale Therapeutic Systems, Inc.|Stabilized bioactive preparations and methods of use|
    CA2273274A1|1997-10-07|1999-04-15|Fuisz Technologies Ltd.|Dosage forms having improved release properties|
    DE59804785D1|1997-11-22|2002-08-22|Roche Diagnostics Gmbh|Improved process for stabilizing proteins|
    EP1952820A3|1998-03-06|2012-06-20|Chugai Seiyaku Kabushiki Kaisha|Protein-free G-CSF formulations|
    ES2210727T3|1998-03-07|2004-07-01|Daewoong Pharmaceutical Co., Ltd.|TOPICAL COMPOSITION CONTAINING HUMAN EPIDERMIC GROWTH FACTOR.|
    AU2746399A|1998-03-09|1999-09-27|Welfide Corporation|Heparin cofactor ii-containing compositions and method for stabilizing the same|
    PL343322A1|1998-04-03|2001-08-13|Chugai Pharmaceutical Co Ltd|Humanized antibody against human tissue factor and process for constructing humanized antibody|
    US6013631A|1998-06-19|2000-01-11|Xoma Corporation|Bactericidal/permeability-increasing protein deletion analogs|
    TR200102259T2|1998-08-21|2002-06-21|Novartis Ag|New oral formulation|
    RU2218935C2|1998-10-16|2003-12-20|Ново Нордиск А/С|Stable concentrated preparative insulin forms for delivery by way of lung|
    JP2002527490A|1998-10-22|2002-08-27|イーライ・リリー・アンド・カンパニー|How to treat sepsis|
    JP2000247903A|1999-03-01|2000-09-12|Chugai Pharmaceut Co Ltd|Long-term stabilized pharmaceutical preparation|
    EP1181039A2|1999-05-24|2002-02-27|Xoma LLC|Therapeutic uses of bpi protein products in humans with otitis media with effusion|
    SK4442002A3|1999-10-01|2003-04-01|Chugai Pharmaceutical Co Ltd|Prevention and treatment of diseases associated with blood coagulation|
    AU1330901A|1999-10-06|2001-05-10|Brigham And Women's Hospital|Compounds and methods for modulating non-transcriptional effects of steroid hormones|
    NL1013456C2|1999-11-02|2001-05-03|Dsm Nv|Crystalline melamine and its application in amino-formaldehyde resins.|
    US6465425B1|2000-02-10|2002-10-15|Alkermes Controlled Therapeutics, Inc.|Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins|
    WO2001070984A2|2000-03-16|2001-09-27|Genentech, Inc.|Anti-tissue factor antibodies with enhanced anticoagulant potency|
    GB2378201B|2000-03-22|2004-08-04|Rotary Drilling Technology Llc|Drill bit stabilizer|
    KR20030016315A|2000-06-30|2003-02-26|산토리 가부시키가이샤|Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components|
    DE10036871A1|2000-07-28|2002-02-14|Pharmasol Gmbh|Dispersions for the formulation of poorly or poorly soluble active ingredients|
    CN1781487A|2000-08-30|2006-06-07|中外制药株式会社|OCT preparations|
    JP2002371009A|2001-04-10|2002-12-26|Kyowa Hakko Kogyo Co Ltd|Method for prolonging duration of pharmacological effect of granulocyte colony-stimulating factor|
    JP5290489B2|2001-11-08|2013-09-18|アッヴィ・バイオセラピューティクス・インコーポレイテッド|Stable liquid pharmaceutical formulation of IGG antibody|
    CA2474943C|2002-02-14|2016-06-07|Chugai Seiyaku Kabushiki Kaisha|Sugar stabilized antibody-containing solution formulations|
    JP4585736B2|2002-04-24|2010-11-24|株式会社日立製作所|Server device|
    JP4610154B2|2002-05-30|2011-01-12|大塚製薬株式会社|Injectable preparation|EP1933868A2|2005-09-12|2008-06-25|NovImmune SA|Anti-cd3 antibody formulations|
    EP1962907A2|2005-12-21|2008-09-03|Wyeth a Corporation of the State of Delaware|Protein formulations with reduced viscosity and uses thereof|
    WO2007108505A1|2006-03-22|2007-09-27|Chugai Seiyaku Kabushiki Kaisha|Erythropoietin solution preparation|
    ES2595638T3|2007-09-26|2017-01-02|Chugai Seiyaku Kabushiki Kaisha|Method to modify the isoelectric point of an antibody by replacing amino acids in a CDR|
    EP2044934A1|2007-10-01|2009-04-08|Institut National De La Sante Et De La Recherche Medicale |Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof|
    EP2052736A1|2007-10-26|2009-04-29|Nycomed Danmark ApS|Parathyroid hormone formulations und uses thereof|
    US8883146B2|2007-11-30|2014-11-11|Abbvie Inc.|Protein formulations and methods of making same|
    CN104645329A|2007-11-30|2015-05-27|Abbvie公司|Protein formulations and methods of making same|
    CA2735376C|2008-09-03|2016-11-29|Octapharma Ag|New protecting compositions for recombinantly produced factor viii|
    JP4885308B2|2009-03-19|2012-02-29|中外製薬株式会社|Formulations containing improved antibody molecules|
    NZ595694A|2009-05-04|2013-09-27|Abbvie Biotechnology Ltd|Stable high protein concentration formulations of human anti-tnf-alpha-antibodies|
    BR112012022223A2|2010-03-01|2016-07-05|Progenics Pharm Inc|concentrated protein formulations and uses thereof|
    SG2014015069A|2010-11-11|2014-07-30|Abbvie Biotechnology Ltd|IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS|
    SI2704742T1|2011-05-02|2017-12-29|Millennium Pharmaceuticals, Inc.|Formulation for anti- 4 7 antibody|
    TWI527590B|2011-06-17|2016-04-01|艾瑞斯貿易公司|Freeze-dried formulations of fgf-18|
    WO2013180316A1|2012-05-29|2013-12-05|주식회사 인트론바이오테크놀로지|Composition capable of improving stability of bacteriophage lysine proteins|
    TWI700300B|2014-09-26|2020-08-01|日商中外製藥股份有限公司|Antibodies that neutralize substances with the function of FVIII coagulation factor |
    CN104761645A|2015-04-30|2015-07-08|山东禹王制药有限公司|Alpha-interferon fusion protein preparation and application|
    CN104906053B|2015-06-12|2018-01-16|北京四环生物制药有限公司|Injection recombined human granulocyte stimulating factors freeze drying powder injection|
    KR101699244B1|2015-08-25|2017-01-24|주식회사 인트론바이오테크놀로지|Composition effective for improving the stability of bacteriophage lysin proteins|
    WO2020002650A1|2018-06-29|2020-01-02|Targovax Asa|A formulation|
    CN112516291A|2019-09-17|2021-03-19|通化安睿特生物制药股份有限公司|Preparation containing human albumin and preparation method thereof|
    法律状态:
    2009-08-20| FGA| Letters patent sealed or granted (standard patent)|
    优先权:
    申请号 | 申请日 | 专利标题
    JP2003053379||2003-02-28||
    JP2003-053379||2003-02-28||
    PCT/JP2004/002429|WO2004075913A1|2003-02-28|2004-02-27|Stabilized preparation containing protein|
    [返回顶部]